5-HT3 receptor antagonists, betablockers ---> SmPC of [granisetron] of EMA
5-HT3 receptor antagonists, such as granisetron, may be associated with arrhythmias or ECG abnormalities. This potentially may have clinical significance in patients who are being treated with antiarrhythmics or beta-blockers.
Ability to drive, betablockers
Dizziness or fatigue may occur
ACE inhibitors, betablockers
When combined with beta-blockers, drugs that decrease arterial pressure can cause or increase hypotension, notably orthostatic.
Aceclofenac, betablockers
Aceclofenac can reduce the anti-hypertensive effect of beta-blocker
Acetylcholine, betablockers
The co-administration can produce bronchospasm.
Acetylsalicylic acid, betablockers
The NSAID can reduce the anti-hypertensive effect of beta-blocker
Aclidinium/formoterol [1], betablockers ---> SmPC of [1] of EMA
Beta-adrenergic blockers may weaken or antagonise the effect of beta2-adrenergic agonists.
Adenosine [1], betablockers ---> SmPC of [1] of eMC
Adenosine may interact with drugs tending to impair cardiac conduction.
Adrenaline [1], non-selective betablockers ---> SmPC of [1] of eMC
Severe hypertension and bradycardia may occur when adrenaline (epinephrine) is administered with nonselective beta-blocking medicinal products.
Adrenaline, betablockers ---> SmPC of [atenolol] of eMC
Concomitant use of sympathomimetic agents, e.g. adrenaline (epinephrine), may counteract the effect of beta-blockers.
AIIRA, betablockers
When combined with beta-blockers, drugs that decrease arterial pressure can cause or increase hypotension, notably orthostatic.
Ajmaline, betablockers
The combination of ajmaline with betablockers may cause an additive inhibitory effect on the AV conduction, the intraventricular stimulus conduction and the force of contraction
Alcohol, betablockers [2] ---> SmPC of [2] of eMC
Alcohol induces increased plasma levels of hepatically metabolised beta blockers
Aldesleukin [1], betablockers ---> SmPC of [1] of eMC
The co-administration may enhance the hypotension caused by aldesleukin.
Alfa-adrenergic receptor blockers, betablockers
When combined with beta-blockers, drugs that decrease arterial pressure can cause or increase hypotension, notably orthostatic.
Alfa2-adrenergic receptor blockers, betablockers ---> SmPC of [esmolol] of eMC
Concomitant use of beta-blockers with moxonidine or alfa2-antagonists (e. g. clonidine) increases the risk of "rebound" hypertension
Alfentanyl [1], betablockers ---> SmPC of [1] of eMC
Treatment with drugs which may depress the heart or increase vagal tone, such as beta-blockers and anaesthetic agents, may predispose to bradycardia or hypotension.
Aliskiren/amlodipine/hydrochlorothiazide [1], betablockers ---> SmPC of [1] of EMA
Concomitant use of thiazide diuretics with beta blockers may increase the risk of hyperglycaemia.
Aliskiren/hydrochlorothiazide [1], betablockers ---> SmPC of [1] of EMA
Concomitant use of thiazide diuretics with beta blockers may increase the risk of hyperglycaemia.
Almasilate, betablockers
Decreased absorption of beta-blocker
Alpha-methyldopa, betablockers
Catecholamine-depleting drugs may have an additive effect when administered concomitantly with beta-blockers. Patients should be closely observed for hypotension.
Aluminium hydroxide, betablockers
Concomitant use of aluminium hydroxide may decrease the absorption and effect of betablockers. Separate administration by at least 2-3 hours
Amidotrizoic acid, betablockers
The co-administration may increase the hypersensitivity reactions
Amifostine, betablockers ---> SmPC of [propranolol] of EMA
Drugs that induce postural hypotension may add their effects to that of beta-blockers.
Amiloride/hydrochlorothiazide, betablockers
The hypotensive effect of amiloride/hydrochlorothiazide can be enhanced by betablockers. The concomitant use also increases the risk of hyperglycemia
Aminophylline, betablockers
Antagonism of bronchodilator effects.
Amiodarone [1], betablockers ---> SmPC of [1] of eMC
Beta blockers and amiodarone: potentiation of negative chronotropic properties and conduction slowing effects may occur. Combined therapy is not recommended
Amisulpride, betablockers ---> SmPC of [esmolol] of eMC
Special caution must be taken when using amisulpride concomitantly with beta-blockers.
Amlodipine [1], betablockers ---> SmPC of [1] of eMC
The blood pressure lowering effects of amlodipine adds to the blood pressure-lowering effects of other medicinal products with antihypertensive properties.
Amlodipine/valsartan/hydrochlorothiazide [1], betablockers ---> SmPC of [1] of EMA
Concomitant use of thiazide diuretics, including hydrochlorothiazide, with beta blockers may increase the risk of hyperglycaemia. Thiazides potentiate the antihypertensive action of other antihypertensive drugs
Anaesthetics, betablockers ---> SmPC of [atenolol] of eMC
Use of beta-blockers with anaesthetic drugs may result in attenuation of the reflex tachycardia and increase the risk of hypotension. Anaesthetic agents causing myocardial depression are best avoided.
Antiarrhythmics, betablockers
The co-administration may cause additive effects resulting in hypotension, and/or marked bradycardia
Antidiabetics, betablockers ---> SmPC of [latanoprost/timolol] of eMC
Beta-blockers may increase the hypoglycaemic effect of antidiabetic agents. Beta-blockers can mask the signs and symptoms of hypoglycaemia
Antihypertensives, betablockers
When combined with beta-blockers, drugs that decrease arterial pressure can cause or increase hypotension, notably orthostatic.
Antimuscarinic agents, betablockers
Antimuscarinic agents may counteract the bradycardia caused by beta blockers.
Apraclonidine [1], betablockers ---> SmPC of [1] of eMC
Since apraclonidine may reduce pulse and blood pressure, caution in using drugs such as beta-blockers (ophthalmic and systemic)
Articaine/epinephrine, non-selective betablockers ---> SmPC of [adrenaline] of eMC
Severe hypertension and bradycardia may occur when adrenaline (epinephrine) is administered with nonselective beta-blocking medicinal products.
Atenolol/nifedipine, betablockers
Atenolol/nifedipine may increase the blood pressure lowering and heart rate modulating effects of concomitant applied antihypertensives (betablocker)
Atracurium [1], betablockers ---> SmPC of [1] of eMC
As with all non-depolarising neuromuscular blocking agents the magnitude and/or duration of a non-depolarising neuromuscular block may be increased as a result of interaction with beta-blockers
Azithromycin, betablockers
The concomitant use with azithromycin may increase the risk of cardiac arrhythmia.
Baclofen, betablockers ---> SmPC of [propranolol] of EMA
Drugs that induce postural hypotension may add their effects to that of beta-blockers.
Bambuterol [1], betablockers ---> SmPC of [1] of eMC
Beta-receptor (including eye-drops), especially those which are non-selective, may partly or totally inhibit the effect of beta-stimulants. Bambuterol and non-selective beta-blockers should not normally be administered concurrently.
Bambuterol [1], non-selective betablockers ---> SmPC of [1] of eMC
Beta-receptor (including eye-drops), especially those which are non-selective, may partly or totally inhibit the effect of beta-stimulants. Bambuterol and non-selective beta-blockers should not normally be administered concurrently.
Bamethane, betablockers
The co-administration may weaken the sympathomimetic effect
Barbiturates, betablockers ---> SmPC of [nebivolol] of eMC
Concomitant use may enhance the hypotensive effect of the beta-blockers (additive effect).
Beclometasone/formoterol/glycopyrronium [1], betablockers ---> SmPC of [1] of EMA
Concomitant use of other beta-adrenergic medicinal products can have potentially additive effects; therefore, caution is required when other beta-adrenergic medicinal products are prescribed concomitantly with formoterol.
Beclometasone/formoterol/glycopyrronium [1], non-selective betablockers ---> SmPC of [1] of EMA
Non-cardioselective beta-blockers (including eye drops) should be avoided in patients taking inhaled formoterol. If they are administered for compelling reasons, the effect of formoterol will be reduced or abolished.
Bendroflumethiazide, betablockers ---> SmPC of [aliskiren/hydrochlorothiazide] of EMA
Concomitant use of thiazide diuretics with beta blockers may increase the risk of hyperglycaemia.
Benzothiazepines, betablockers ---> SmPC of [atenolol] of eMC
Beta-blockers should not be given in combination with calcium channel blockers of diltiazem type since this may cause bradycardia, hypotension, heart failure and asystole and may increase auriculo-ventricular conduction time.
Bepridil, betablockers
The combination may worsen the negative inotropic effects particularly in patients with impaired ventricular function and/or SA or AV conduction abnormalities
Beta-adrenergic agonists, betablockers
Beta-adrenergic blockers (including eye drops) can weaken or inhibit the effect of beta2-adrenergic agonists, such as formoterol.
Beta-adrenergic agonists, betablockers
Beta-adrenergic blockers may weaken or antagonise the effect of beta2-adrenergic agonists.
Beta-adrenergic agonists, betablockers ---> SmPC of [bambuterol] of eMC
Beta-blocking agents (including eye drops), especially the non-selective ones such as propranolol, may partially or totally inhibit the effect of beta-stimulants.
Beta-adrenergic agonists, non-selective betablockers ---> SmPC of [bambuterol] of eMC
Beta-blocking agents (including eye drops), especially the non-selective ones such as propranolol, may partially or totally inhibit the effect of beta-stimulants.
Beta2-adrenergic agonists, betablockers ---> SmPC of [vilanterol] of EMA
Betablockers may weaken or antagonise the effect of beta2-adrenergic agonists. Concurrent use of either non-selective or selective betablockers should be avoided unless there are compelling reasons for their use.
Beta2-adrenergic agonists, non-selective betablockers
Non-cardioselective beta blockers oppose the bronchodilator effects and in asthmatics can enhance the bronchial obstruction
Betablockers metabolised by CYP2D6, dronedarone [2] ---> SmPC of [2] of EMA
Dronedarone, CYP2D6 inhibitor, may increase the exposition of beta blocker metabolized by CYP2D6. In clinical studies, bradycardia was more frequently observed when dronedarone was given in combination with beta-blockers.
Betablockers [1], estrogens ---> SmPC of [1] of eMC
Concurrent use of oestrogens and betablockers may decrease the antihypertensive effect of betablockers because oestrogen-induced fluid retention may lead to increased blood pressure.
Betablockers, betablockers ---> SmPC of [metoprolol] of eMC
Care should be taken when beta-blockers are given in combination with other beta-blockers (ie eye drops)
Betablockers, betaxolol
Potential additive effect either on the intraocular pressure or on the systemic effects of beta-blockers
Betablockers, bimatoprost/timolol [2] ---> SmPC of [2] of EMA
There is a potential for additive effects resulting in hypotension, and/or marked bradycardia when ophthalmic beta-blockers solution is administered concomitantly with oral beta-adrenergic blocking agents
Betablockers, bisoprolol [2] ---> SmPC of [2] of eMC
Topical beta-blocking agents (e.g. eye drops for glaucoma treatment) may add to the systemic effects of bisoprolol.
Betablockers, brinzolamide/timolol [2] ---> SmPC of [2] of EMA
There is a potential for additive effects resulting in hypotension, and/or marked bradycardia when ophthalmic beta-blockers solution is administered concomitantly with oral beta-adrenergic blocking agents
Betablockers, bupivacaine
The co-administration may have an additive inhibitor effect on AV conduction, intraventricular impulse spread and contraction force
Betablockers, bupivacaine/meloxicam [2] ---> SmPC of [2] of EMA
NSAIDs may decrease the antihypertensive effect of ACE inhibitors, angiotensin-II antagonists, or beta-blockers (including propranolol).
Betablockers, calcium antagonists ---> SmPC of [amlodipine] of eMC
Calcium channel blockers generally potentiate the pharmacologic effects of beta-blockers. Patients taking both agents should be carefully monitored for adverse cardiovascular events.
Betablockers, captopril [2] ---> SmPC of [2] of eMC
Concomitant use of betablockers and captopril may increase the hypotensive effects of captopril.
Betablockers, carbachol
Increased intraocular hypotensive effect
Betablockers, carteolol [2] ---> SmPC of [2] of eMC
There is a potential for additive effects resulting in hypotension and/or marked bradycardia when ophthalmic beta-blockers solution is administered concomitantly with beta-adrenergic blocking agents
Betablockers, catecholamine depleting drugs ---> SmPC of [esmolol] of eMC
Catecholamine-depleting agents may have an additive effect when given with beta-blocking agents. Patients should be closely observed for evidence of hypotension or marked bradycardia
Betablockers, centrally-acting antihypertensives
The co-administration may enhance the hypotensive effect and further decrease the central sympathetic tonus
Betablockers, centrally-acting antihypertensives
When combined with beta-blockers, drugs that decrease arterial pressure can cause or increase hypotension, notably orthostatic.
Betablockers, chlortalidone ---> SmPC of [aliskiren/hydrochlorothiazide] of EMA
Concomitant use of thiazide diuretics with beta blockers may increase the risk of hyperglycaemia.
Betablockers, cibenzoline
Class I anti-arrhythmic drugs may increase atrial-conduction time and induce negative inotropic effect when administered concomitantly with beta-blockers.
Betablockers, cimetidine
Cimetidine may reduce the hepatic metabolism of beta-blockers, resulting in increased plasma levels of beta-blocker and prolonged serum half-life. Marked bradycardia may occur.
Betablockers, class I antiarrhythmic agents ---> SmPC of [propranolol] of eMC
Class I anti-arrhythmic drugs may increase atrial-conduction time and induce negative inotropic effect when administered concomitantly with beta-blockers.
Betablockers, class IA antiarrhythmic agents ---> SmPC of [propranolol] of eMC
Class I anti-arrhythmic drugs may increase atrial-conduction time and induce negative inotropic effect when administered concomitantly with beta-blockers.
Betablockers, class IB antiarrhythmic agents ---> SmPC of [propranolol] of eMC
Class I anti-arrhythmic drugs may increase atrial-conduction time and induce negative inotropic effect when administered concomitantly with beta-blockers.
Betablockers, class IC antiarrhythmic agents ---> SmPC of [propranolol] of eMC
Class I anti-arrhythmic drugs may increase atrial-conduction time and induce negative inotropic effect when administered concomitantly with beta-blockers.
Betablockers, class III antiarrhythmic agents
The concomitant use should be done with caution as the effect on atrioventricular conduction time may be potentiated
Betablockers, clenbuterol
The beta-blocker may abolish the effect of clenbuterol
Betablockers, clonazepam
Enhanced hypotensive effect
Betablockers, clonidine [2] ---> SmPC of [2] of eMC
Concomitant use of clonidine with beta-blockers can cause bradycardia or dysrhythmia (AV-block) in isolated cases. It cannot be ruled out that concomitant administration will cause or potentiate peripheral vascular disorders.
Betablockers, clopamide
Increased hypotensive effect
Betablockers, clopidogrel/acetylsalicylic acid [2] ---> SmPC of [2] of EMA
Interactions with betablockers and higher (anti-inflammatory) doses of ASA have been reported
Betablockers, coxibs ---> SmPC of [propranolol] of EMA
Non-steroidal anti-inflammatory drugs (NSAIDS) have been reported to blunt the antihypertensive effect of beta-blocking agents.
Betablockers, crizotinib [2] ---> SmPC of [2] of EMA
Bradycardia has been reported during clinical studies; therefore, use crizotinib with caution due to the risk of excessive bradycardia when used in combination with other bradycardic agents
Betablockers, cyclooxygenase inhibitors
The co-administration may cause a further worsening of renal function. The concomitant use should be done with caution
Betablockers, dantrolene
Hyperkalemia and myocardial depression have been observed in malignant hyperthermia-susceptible patients receiving intravenous dantrolene sodium and concomitant betablockers.
Betablockers, desflurane
Desflurane may potentiate the hypotensive effect when is administered with other antihypertensive drugs
Betablockers, dexibuprofen [2] ---> SmPC of [2] of eMC
NSAIDs may reduce the efficacy of beta-blockers, possibly due to inhibition of the formation of vasodilatory prostaglandins.
Betablockers, dexketoprofen [2] ---> SmPC of [2] of eMC
Treatment with a NSAID may decrease their antihypertensive effect via inhibition of prostaglandin synthesis.
Betablockers, dexmedetomidine [2] ---> SmPC of [2] of EMA
The possibility of enhanced hypotensive and bradycardic effects should be considered in patients receiving other medicinal products causing these effects, for example beta blockers
Betablockers, dextropropoxyphene
Increased bioavailability and decreased clearance of betablocker
Betablockers, diazepam [2] ---> SmPC of [2] of eMC
Enhanced hypotensive effect
Betablockers, diazoxide
Diazoxide may potentiate the effect of hypotensive drugs, what cause a further hypotension
Betablockers, diclofenac [2] ---> SmPC of [2] of eMC
NSAIDs (especially indometacin) may reduce the antihypertensive effects of beta-blockers possibly by inhibiting renal prostaglandin synthesis and/or causing sodium and fluid retention.
Betablockers, digital glycosides ---> SmPC of [oxprenolol] of eMC
Beta-blockers and digitalis glycosides may be additive in their depressant effect on myocardial conduction, particularly through the atrioventricular node, resulting in bradycardia or heart block.
Betablockers, digitoxin
Increased bradycardiac effect
Betablockers, digoxin ---> SmPC of [carvedilol] of eMC
Digoxin, in association with beta-adrenoceptor blocking drugs, may increase atrio-ventricular conduction time.
Betablockers, dihydralazine
The co-administration may increase the hypotensive effect
Betablockers, dihydropyridines ---> SmPC of [propranolol] of EMA
Both agents may induce hypotension and/or heart failure in patients whose cardiac function is partially controlled because of additive inotropic effects. Concomitant use may reduce the reflex sympathetic response
Betablockers, diltiazem [2] ---> SmPC of [2] of eMC
Betablockers: Possibility of rhythm disturbances (pronounced bradycardia, sinus arrest), sino-atrial and atrio-ventricular conduction disturbances and heart failure (synergistic effect).
Betablockers, dipotassium clorazepate
The combination of CNS depressors may mutually potentiate the depressor effect on the CNS
Betablockers, disopyramide [2] ---> SmPC of [2] of eMC
Antiarrhythmic combination should be avoided except under certain circumstances
Betablockers, distigmine
The co-administration may decrease the distigmine effect and cause a long-lasting bradycardia and increased hypotension
Betablockers, diuretics
When combined with beta-blockers, drugs that decrease arterial pressure can cause or increase hypotension, notably orthostatic.
Betablockers, dopamine agonists ---> SmPC of [propranolol] of EMA
Drugs that induce postural hypotension may add their effects to that of beta-blockers.
Betablockers, dopamine [2] ---> SmPC of [2] of eMC
The cardiac effects of dopamine are antagonised by beta-adrenergic blocking agents
Betablockers, dorzolamide/timolol [2] ---> SmPC of [2] of eMC
The effect on intra-ocular pressure or the known effects of systemic beta-blockade may be potentiated when timolol is given to the patients already receiving a systemic beta-blocking agent.
Betablockers, doubutamine [2] ---> SmPC of [2] of eMC
The inotropic effects of dobutamine on the heart are reversed by concomitant administration of beta-blockers. Dobutamine may be ineffective or may have a slight vasoconstricting effect in patients who have recently received beta-blockers.
Betablockers, doxepin
The co-administration may potentiate the hypotensive and thymoleptic effect of doxepin
Betablockers, enalapril [2] ---> SmPC of [2] of eMC
Enalapril can be safely administered concomitantly with acetyl salicylic acid (at cardiologic doses), thrombolytics and betablockers.
Betablockers, ephedrine
Concomitant use of ephedrine and betablocker blocks the cardiac and bronchodilator effects of ephedrine
Betablockers, ergot derivatives ---> SmPC of [esmolol] of eMC
Concomitant administration of ergot alkaloids with beta-blockers may enhance the vasoconstrictive action of ergot alkaloids.
Betablockers, ergotamine
Caution is recommended with the co-administration of betablocker und ergot derivatives. The co-administration may enhance the vasoconstrictor effect of ergot derivatives.
Betablockers, etilefrine
The co-administration may abolish partial or totally the etilefrine effect. The combination should be avoided due to the possibility of reflex bradycardia
Betablockers, felodipine
The co-administration may increase the risk of hypotension, and cardiac failure may occur in patients with latent cardiac insufficiency
Betablockers, felodipine/metoprolol
Care should be taken when beta-blockers (e. g. eye drops) are given in combination other beta-blockers.
Betablockers, fenoterol
Beta-blocker may abolish the fenoterol effect and in patients with bronchial asthma may cause a severe bronchial constriction
Betablockers, ferumoxsil
Efficacy decrease of cardiovascular mechanisms that compensate the blood pressure disorders
Betablockers, fingolimod [2] ---> SmPC of [2] of EMA
Treatment with Gilenya should not be initiated in patients receiving beta blockers, or other substances which may decrease heart rate because of the potential additive effects on heart rate
Betablockers, flecainide [2] ---> SmPC of [2] of eMC
The possibility of additive negative inotropic effects of Class II antiarrhythmics, i.e. beta-blockers, with flecainide should be recognised.
Betablockers, floctafenine
Beta-adrenergic blocking agents may impede the compensatory cardiovascular reactions associated with hypotension or shock that may be induced by floctafenine.
Betablockers, floctafenine ---> SmPC of [esmolol] of eMC
Special caution must be taken when using floctafenine concomitantly with beta-blockers.
Betablockers, fluorescein [2] ---> SmPC of [2] of eMC
The concomitant use of fluorescein solution for injection with beta-blocking agents (including eye-drops solutions) may rarely provoke severe anaphylactic reactions
Betablockers, fluphenazine
Betablockers: Plasma levels of both active principles may be increased. It is recommended to reduce the doses of both active principles
Betablockers, flurazepam [2] ---> SmPC of [2] of eMC
Enhancement of the central depressive effect may occur if benzodiazepines are combined with centrally-acting drugs
Betablockers, fluticasone
Avoid the use of beta-blockers, unless there are compelling reasons for their use
Betablockers, formoterol [2] ---> SmPC of [2] of eMC
Beta-adrenergic blockers may weaken or antagonise the effect of formoterol. Therefore formoterol should not be given together with beta-adrenergic blockers (including eye drops) unless there are compelling reasons for their use.
Betablockers, formoterol/glycopyrronium/budesonide [2] ---> SmPC of [2] of EMA
Beta-adrenergic blockers (including eye drops) can weaken or inhibit the effect of formoterol. Concurrent use of beta-adrenergic blockers should be avoided unless the expected benefit outweighs the potential risk.
Betablockers, fosinopril [2] ---> SmPC of [2] of eMC
Combination with of fosinopril with other anti-hypertensive agents may increase the anti-hypertensive effect.
Betablockers, gadoteric acid
Decreased efficacy of cardiovascular compensation mechanisms that occur in blood pressure disorder
Betablockers, galantamine [2] ---> SmPC of [2] of eMC
As expected with cholinomimetics, a pharmacodynamic interaction is possible with medicinal products that significantly reduce the heart rate
Betablockers, gallopamil
Mutual enhancement of cardiovascular effects. The i.v. administration of beta-blocker during gallopamil therapy is contraindicated (except intensive care)
Betablockers, ganglionic blockers ---> SmPC of [metoprolol] of eMC
Care should be taken when beta-blockers are given in combination with sympathetic ganglion blocking agents
Betablockers, general anesthetics ---> SmPC of [atenolol] of eMC
Use of beta-blockers with anaesthetic drugs may result in attenuation of the reflex tachycardia and increase the risk of hypotension. Anaesthetic agents causing myocardial depression are best avoided.
Betablockers, glibenclamide [2] ---> SmPC of [2] of EMA
Under the influence of sympatholytic medicinal products, the signs of adrenergic counter-regulation to hypoglycaemia may be reduced or absent.
Betablockers, gliclazide [2] ---> SmPC of [2] of eMC
Potentiation of the blood glucose lowering effect and thus, in some instances, hypoglycaemia may occur when beta-blockers are taken
Betablockers, glimepiride [2] ---> SmPC of [2] of eMC
The combination may lead to either potentiation or weakening of the blood glucose lowering effect. Under the influence of sympatholytic medicinal products the signs of adrenergic counter-regulation to hypoglycaemia may be reduced or absent.
Betablockers, glipizide
All beta-blockers mask some of the symptoms of hypoglycaemia, i.e. palpitations and tachycardia. Most non cardioselective beta-blockers increase the incidence and severity of hypoglycaemia.
Betablockers, gliquidone
Hypoglycemic reactions may occur as expression of enhancement effect of gliquidone with gliquidone is co-administered with betablockers and also mask the symptoms of a hypoglycemia
Betablockers, glucagon
Glucagon treatment results in catecholamine release from the adrenal glands, and concomitant use of beta-blockers could result in unopposed alpha-adrenergic stimulation and consequently, a greater increase in blood pressure
Betablockers, glucagon [2] ---> SmPC of [2] of EMA
Patients taking beta-blockers might be expected to have a greater increase in both pulse and blood pressure, an increase of which will be transient because of glucagon's short half-life.
Betablockers, glycerol trinitrate
Treatment with other agents with hypotensive effects may potentiate the hypotensive effect of glyceryl trinitrate.
Betablockers, glycerol trinitrate [2] ---> SmPC of [2] of eMC
Treatment with other agents with hypotensive effects may potentiate the hypotensive effect of glyceryl trinitrate.
Betablockers, guanethidine
Catecholamine-depleting drugs may have an additive effect when administered concomitantly with beta-blockers. Patients should be closely observed for hypotension.
Betablockers, guanfacin
The combination may enhance the hypotensive effect and decrease the central sympathetic tonus (reduction of heart rate and cardiac output, vasodilation)
Betablockers, halogenated anaesthetics ---> SmPC of [propranolol] of eMC
Concomitant use of beta-adrenergic antagonists and anaesthetics may attenuate reflex tachycardia and increase the risk of hypotension. Sudden withdrawal of beta-blocker treatment should be avoided if possible.
Betablockers, histamine dihydrochloride [2] ---> SmPC of [2] of EMA
Beta-blockers should be used with caution during treatment with histamine. They may increase the toxicity of histamine
Betablockers, human insulin [2] ---> SmPC of [2] of EMA
Possible reduction of the patient's insulin requirement. Beta-blockers may mask the symptoms of hypoglycaemia.
Betablockers, hydralazine
Hydralazine may induce increased plasma levels of hepatically metabolised beta-blockers.
Betablockers, hydrochinone
Class I anti-arrhythmic drugs may increase atrial-conduction time and induce negative inotropic effect when administered concomitantly with beta-blockers.
Betablockers, hydrochlorothiazide ---> SmPC of [amlodipine/valsartan/hydrochlorothiazide] of EMA
Concomitant use of thiazide diuretics, including hydrochlorothiazide, with beta blockers may increase the risk of hyperglycaemia. Thiazides potentiate the antihypertensive action of other antihypertensive drugs
Betablockers, hydroquinidine
Alterations of contractility, automatism and conduction (suppression of sympathetic compensatory mechanisms)
Betablockers, hydroxychloroquine
Hydroxychloroquine may decrease the metabolism of some betablockers
Betablockers, ibuprofen ---> SmPC of [atenolol/chlortalidone] of eMC
Concomitant use of prostaglandin synthetase-inhibiting drugs may decrease the hypotensive effects of beta-blockers.
Betablockers, iloprost [2] ---> SmPC of [2] of EMA
Iloprost may increase the effects of vasodilatators and antihypertensive agents and then favour the risk of hypotension
Betablockers, IMAOs ---> SmPC of [bisoprolol] of eMC
Combination of a MAO inhibitor with a beta-blocker can cause an increase of the pharmacodynamic effects and an increase in blood pressure up to hypertension crises.
Betablockers, imidapril [2] ---> SmPC of [2] of eMC
Imidapril may be used concomitantly with acetylsalicylic acid (when used as a thrombolytic), thrombolytics, and beta-blockers.
Betablockers, imipramine
The co-administration may potentiate the hypotensive effects of the beta blocker
Betablockers, indacaterol [2] ---> SmPC of [2] of EMA
Indacaterol should not be given together with beta-adrenergic blockers (including eye drops) unless there are compelling reasons for their use
Betablockers, indacaterol/glycopyrronium [2] ---> SmPC of [2] of EMA
Indacaterol should not be given together with beta-adrenergic blockers (including eye drops) unless there are compelling reasons for their use
Betablockers, indometacin ---> SmPC of [atenolol/chlortalidone] of eMC
Concomitant use of prostaglandin synthetase-inhibiting drugs may decrease the hypotensive effects of beta-blockers.
Betablockers, insulin
The beta-blocker may increase the hypoglycaemic effect of insulin. Blockade of beta-adrenoreceptors may mask the symptoms of hypoglycaemia
Betablockers, insulin aspart [2] ---> SmPC of [2] of EMA
Possible reduction of the insulin requirements. Beta-blockers may mask the symptoms of hypoglycaemia.
Betablockers, insulin degludec [2] ---> SmPC of [2] of EMA
Possible reduction of the insulin requirements. Beta-blockers may mask the symptoms of hypoglycaemia.
Betablockers, insulin degludec/insulin aspart [2] ---> SmPC of [2] of EMA
Possible reduction of the insulin requirements. Beta-blockers may mask the symptoms of hypoglycaemia.
Betablockers, insulin degludec/liraglutide [2] ---> SmPC of [2] of EMA
Possible reduction of the Xultophy requirements. Beta-blockers may mask the symptoms of hypoglycaemia.
Betablockers, insulin detemir [2] ---> SmPC of [2] of EMA
Possible reduction of the insulin requirements. Beta-blockers may mask the symptoms of hypoglycaemia.
Betablockers, insulin glargin [2] ---> SmPC of [2] of EMA
Beta-blockers may either potentiate or weaken the blood-glucose-lowering effect of insulin. Under the influence of sympatholytic medicinal products such as beta-blockers, the signs of adrenergic counter-regulation may be reduced or absent.
Betablockers, insulin glargine/lixisenatide [2] ---> SmPC of [2] of EMA
This combination may either potentiate or weaken the blood-glucose-lowering effect of insulin.
Betablockers, insulin glulisin [2] ---> SmPC of [2] of EMA
The signs of adrenergic counter-regulation may be reduced or absent.
Betablockers, insulin lispro [2] ---> SmPC of [2] of EMA
Insulin requirements may be reduced in the presence of medicinal products with hypoglycaemic activity
Betablockers, interleukin-2 [2] ---> SmPC of [2] of eMC
The co-administration may enhance the hypotension caused by aldesleukin.
Betablockers, iobitridol
The use of betablocker increases the risk of hypersensitivity reactions to contrast media
Betablockers, iodinated contrast media ---> SmPC of [iomeprol] of eMC
It has been reported that cardiac and/or hypertensive patients under treatment with diuretics, ACE-inhibitors, and/or beta blocking agents are at higher risk of adverse reactions when administered iodinated contrast media.
Betablockers, iohexol
The use of betablocker increases the risk of hypersensitivity reactions to contrast media
Betablockers, iomeprol [2] ---> SmPC of [2] of eMC
It has been reported that cardiac and/or hypertensive patients under treatment with diuretics, ACE-inhibitors, and/or beta blocking agents are at higher risk of adverse reactions when administered iodinated contrast media.
Betablockers, iopamidol [2] ---> SmPC of [2] of eMC
Concomitant administration of iopamidol and betablockers can exacerbate severe hypersensitivity reactions.
Betablockers, iopromide
The use of betablocker increases the risk of hypersensitivity reactions to contrast media
Betablockers, iotrolan
The use of betablocker increases the risk of hypersensitivity reactions to contrast media
Betablockers, ioxaglic acid
Decreased efficacy of cardiovascular compensation mechanisms that occur in blood pressure disorder
Betablockers, irbesartan [2] ---> SmPC of [2] of EMA
Other antihypertensive agents may increase the hypotensive effects of irbesartan; however Aprovel has been safely administered with other antihypertensive agents, such as beta-blockers, long-acting calcium channel blockers, and thiazide diuretics.
Betablockers, irreversible non-selective MAO-inhibitors
Enhanced hypotensive effect of the beta-blocker but also the risk of hypertensive crisis.
Betablockers, isoflurane [2] ---> SmPC of [2] of eMC
Cardiovascular compensation reactions may be impaired by beta-blockers.
Betablockers, isoniazid
Metabolism inhibition of isoniazid and increase of its plasma levels
Betablockers, isoprenaline
Betablocker may counteract the isoprenaline effect.
Betablockers, isosorbide dinitrate [2] ---> SmPC of [2] of eMC
Concurrent intake of drugs with blood pressure lowering properties may potentiate the hypotensive effect
Betablockers, isosorbide mononitrate [2] ---> SmPC of [2] of eMC
Beta-blocking drugs have a different pharmacological action in angina and may have a complimentary effect when co-administered with isosorbide mononitrate.
Betablockers, isradipine
The co-administration may enhance the negative inotropic effect
Betablockers, ivabradine [2] ---> SmPC of [2] of EMA
In pivotal phase III clinical trials betablockers were routinely combined with ivabradine with no evidence of safety concerns
Betablockers, ketoprofen [2] ---> SmPC of [2] of eMC
Risk of decreased antihypertensive potency (inhibition of vasodilator prostaglandins by NSAIDs).
Betablockers, ketorolac
NSAIDs may reduce the effect of anti-hypertensive medicinal products.
Betablockers, lacidipine [2] ---> SmPC of [2] of eMC
Co-administration of lacidipine with other agents recognised to have a hypotensive effect may have an additive hypotensive effect.
Betablockers, lanreotide [2] ---> SmPC of [2] of eMC
Concomitant administration of bradycardia-inducing drugs (e.g. beta blockers) may have an additive effect on the slight reduction of heart rate associated with lanreotide.
Betablockers, latanoprost/timolol [2] ---> SmPC of [2] of eMC
The effect on intraocular pressure or the known effects of systemic beta-blockade may be potentiated when latanoprost/timolol is given to patients already receiving an oral beta-blocking agent
Betablockers, lercanidipine [2] ---> SmPC of [2] of eMC
Decreased bioavailability of lercanidipine. Lercanidipine may be safely administered with beta-adrenoceptor blocking drugs, but dose adjustment may be required.
Betablockers, levobunolol [2] ---> SmPC of [2] of eMC
There is a potential for additive effects resulting in hypotension, and/or marked bradycardia when ophthalmic beta-blocker solutions are administered concomitantly with beta-adrenergic blocking agents
Betablockers, levodopa ---> SmPC of [propranolol] of EMA
Drugs that induce postural hypotension may add their effects to that of beta-blockers.
Betablockers, levomepromazine
The co-administration of levomepromazine with bradycardic drugs exacerbates the QT prolongation and may increase the risk of ventricular arrhytmias.
Betablockers, levosimendan
The infusion of levosimendan can be used without loss of efficacy in patients who are treated with betablockers
Betablockers, levothyroxine [2] ---> SmPC of [2] of eMC
Beta blockers may decrease the peripheral conversion of levothyroxine to triiodothyronine.
Betablockers, lidocaine ---> SmPC of [lidocaine/prilocaine] of EMA
The betablocker reduces the clearance of lidocaine and may cause toxic plasma concentrations. Concomitant use should be avoided
Betablockers, lidocaine/prilocaine [2] ---> SmPC of [2] of EMA
Medicinal products that reduce the clearance of lidocaine may cause potentially toxic plasma concentrations when lidocaine is given intravenously in repeated high doses over a long time period (30 hours).
Betablockers, liothyronine
Liothyronine accelerates metabolism of beta-blockers
Betablockers, lorazepam [2] ---> SmPC of [2] of eMC
Enhanced hypotensive effect
Betablockers, lormetazepam
Type and scope of interactions are unpredictable in long-term therapy with drugs affecting respiratory and circulatory function
Betablockers, lornoxicam
The NSAID can reduce the anti-hypertensive effect of beta-blocker
Betablockers, manidipine
The antihypertensive effect of manidipine can be enhanced by the co-administration of betablockers
Betablockers, mefloquine
Concomitant administration of mefloquine and other drugs known to alter cardiac conduction might contribute to a prolongation of the QTc interval.
Betablockers, mefruside
The co-administration may increase the antihypertensive effects
Betablockers, meglumine and sodium ioxitalamate
The use of betablocker increases the risk of hypersensitivity reactions to contrast media
Betablockers, meglumine ioxitalamate
The use of betablocker increases the risk of hypersensitivity reactions to contrast media
Betablockers, meloxicam
The NSAID can reduce the anti-hypertensive effect of beta-blocker
Betablockers, mepivacaine
The co-administration may have an additive inhibitory effect on AV conduction, intraventricular impulse spreading and contraction force
Betablockers, metacholine
The response to methacholine may be exaggerated or prolonged. The co-administration is contraindicated
Betablockers, metformin ---> SmPC of [brinzolamide/timolol] of EMA
The beta-blocker may increase the hypoglycaemic effect of insulin. Blockade of beta-adrenoreceptors may mask the symptoms of hypoglycaemia
Betablockers, methyldopa
Concomitant use of methyldopa and betablockers may enhance the hypotensive effect.
Betablockers, methylergometrine
Caution is recommended with the co-administration of betablocker und methylergometrine. The co-administration may enhance the vasoconstrictor effect of ergot derivatives.
Betablockers, methysergide
Ischemia with risk of gangrene
Betablockers, metildigoxin
Enhanced bradycardic effect
Betablockers, metoprolol [2] ---> SmPC of [2] of eMC
Care should be taken when beta-blockers are given in combination with other beta-blockers (ie eye drops)
Betablockers, mexiletine
Class I anti-arrhythmic drugs may increase atrial-conduction time and induce negative inotropic effect when administered concomitantly with beta-blockers.
Betablockers, midazolam
Enhanced hypotensive effect
Betablockers, midodrine
The bradycardic efect of betablocker can be enhanced by midodrine
Betablockers, mifamurtide
Caution should be exercised when starting concomitant use of mifamurtide with antihypertensives and patients should be monitored for possible adverse reactions.
Betablockers, minoxidil
Betablocker suppresses the reflex tachycardia and the increase of plasma renin activity and aldosterone secretion associated with minoxidil
Betablockers, molsidomine
The co-administration may potentiate the hypotensive effect
Betablockers, moxonidine ---> SmPC of [esmolol] of eMC
Concomitant use of beta-blockers with moxonidine or alfa2-antagonists (e. g. clonidine) increases the risk of "rebound" hypertension
Betablockers, muscle relaxants (non-depolarizing) ---> SmPC of [atracurium] of eMC
As with all non-depolarising neuromuscular blocking agents the magnitude and/or duration of a non-depolarising neuromuscular block may be increased as a result of interaction with beta-blockers
Betablockers, naftidrofuryl
Naftidrofuryl may potentiate the effect of beta-blocker
Betablockers, naphazoline
The co-administration may cause complex interactions
Betablockers, naproxen [2] ---> SmPC of [2] of eMC
Concomitant administration of naproxen with beta blockers may reduce their antihypertensive effect
Betablockers, naproxen/esomeprazole [2] ---> SmPC of [2] of eMC
Naproxen and other NSAIDs can reduce the antihypertensive effect of propranolol and other beta-blockers.
Betablockers, naratriptan [2] ---> SmPC of [2] of eMC
There is no evidence of a pharmacokinetic interaction of naratriptan with betablockers
Betablockers, neostigmine
When using neostigmine are possible long-lasting bradycardias in pretreatment with betablockers
Betablockers, neuroleptics ---> SmPC of [propranolol] of EMA
Drugs that induce postural hypotension may add their effects to that of beta-blockers.
Betablockers, nicardipine [2] ---> SmPC of [2] of eMC
Nicardipine may be used in combination with beta-blocking and other anti-hypertensive drugs but the possibility of an additive effect resulting in postural hypotension should be considered.
Betablockers, nicergoline
Nicergoline may enhance the heart effects of betablocker.
Betablockers, nicomorphine
Nicomorphine may enhance the effect of betablocker
Betablockers, nicotine ---> SmPC of [propranolol] of eMC
Smoking tobacco may oppose the effects of beta blockers in the treatment of angina or hypotension.
Betablockers, nifedipine [2] ---> SmPC of [2] of eMC
Nifedipine may be used in combined therapy with other antihypertensive agents including beta-blocker drugs, but the possibility of an additive effect resulting in postural hypotension should be borne in mind.
Betablockers, nilvadipine
The co-administration may cause heart failure.
Betablockers, nimodipine [2] ---> SmPC of [2] of eMC
Nimodipine may increase the blood pressure lowering effect of concomitant antihypertensives
Betablockers, nisoldipine
The co-administration may cause heart failure.
Betablockers, nitrendipine
The co-administration may increase the risk of hypotension, and cardiac failure may occur in patients with latent cardiac insufficiency
Betablockers, nitroglycerine [2] ---> SmPC of [2] of eMC
Treatment with other agents with hypotensive effects may potentiate the hypotensive effect of glyceryl trinitrate.
Betablockers, non-selective MAO-inhibitors
Enhanced hypotensive effect of the beta-blocker but also the risk of hypertensive crisis.
Betablockers, noradrenaline ---> SmPC of [norepinephrine] of eMC
The co-administration of noradrenaline with beta-blockers may decrease the hypertensive effect of noradrenaline
Betablockers, norepinephrine
The co-administration of noradrenaline with beta-blockers may decrease the hypertensive effect of noradrenaline
Betablockers, norfenefrine
The co-administration may increase the sympathomimetic effect
Betablockers, NSAID ---> SmPC of [propranolol] of EMA
Non-steroidal anti-inflammatory drugs (NSAIDS) have been reported to blunt the antihypertensive effect of beta-blocking agents.
Betablockers, opipramol
The co-administration may modify the plasma levels of both active principles
Betablockers, oral antidiabetics ---> SmPC of [brinzolamide/timolol] of EMA
The beta-blocker may increase the hypoglycaemic effect of antidiabetic agent. Blockade of beta-adrenoreceptors may mask the symptoms of hypoglycaemia
Betablockers, orciprenaline
Betablockers may significantly decrease the effect of orciprenaline and cause bronchospasms
Betablockers, organic nitrates ---> SmPC of [propranolol] of EMA
Drugs that induce postural hypotension may add their effects to that of beta-blockers.
Betablockers, orthostatic hypotension ---> SmPC of [propranolol] of EMA
Drugs that induce postural hypotension may add their effects to that of beta-blockers.
Betablockers, oxaprozin
The NSAID can reduce the anti-hypertensive effect of beta-blocker
Betablockers, oxazepam
Enhancement of other CNS depressant drugs
Betablockers, oxybuprocaine
Decreased effect of betablocker
Betablockers, ozanimod [2] ---> SmPC of [2] of EMA
Caution should be applied when ozanimod is initiated in patients receiving treatment with a betablocker or a calcium-channel blocker (e.g. diltiazem and verapamil) because of the potential for additive effects on lowering HR.
Betablockers, pancuronium
Possible enhancement of pancuronium effect and the intensity of neuromuscular block
Betablockers, parasympathomimetics
The co-administration may prolong the atrioventricular conduction time and cause additive effects resulting in hypotension, and/or marked bradycardia
Betablockers, parecoxib [2] ---> SmPC of [2] of EMA
Inhibition of prostaglandins by NSAIDs, including COX-2 inhibitors, may diminish the effect of beta-blockers
Betablockers, pasireotide [2] ---> SmPC of [2] of EMA
Clinical monitoring of heart rate, notably at the beginning of treatment, is recommended in patients receiving pasireotide concomitantly with bradycardic medicinal products
Betablockers, PDE5 inhibitors ---> SmPC of [propranolol] of EMA
Drugs that induce postural hypotension may add their effects to that of beta-blockers.
Betablockers, pentaerythritol tetranitrate
The co-administration may potentiate the hypotensive effect
Betablockers, pentamidine
The co-administration may cause asthmoid states
Betablockers, perindopril
The co-administration may enhance the hypotensive effect
Betablockers, peripheral muscle relaxants
The neuromuscular blockade by peripheral muscle relaxants may be potentiate by betablockers
Betablockers, phenazone
Concomitant use of phenazone and betablockers delays the elimination of phenazone. There is the possibility of an accumulation
Betablockers, phenothiazines ---> SmPC of [nebivolol] of eMC
Concomitant use may enhance the hypotensive effect of the beta-blockers (additive effect).
Betablockers, phenylalkylamines ---> SmPC of [carvedilol] of eMC
As with other beta-blockers, ECG and blood pressure should be monitored closely when concomitantly administering calcium-channel-blockers of the verapamil type due to the risk of AV conduction disorder or risk of cardiac failure (synergetic effect)
Betablockers, phenylephrine
The interaction of phenylephrine with beta und alfa blocker may be complex
Betablockers, pilocarpine [2] ---> SmPC of [2] of eMC
Pilocarpine should be administered with caution to patients taking beta adrenergic antagonists because of the possibility of conduction disturbances.
Betablockers, pimozide
The co-administration may enhance the hypotensive effect
Betablockers, pioglitazone/glimepiride [2] ---> SmPC of [2] of EMA
Betablockers may lead to either potentiation or weakening of the blood glucose lowering effect.
Betablockers, pipobroman
Antagonism
Betablockers, piretanide
The hypotensor effect of piretanide may be potentiated
Betablockers, piroxicam ---> SmPC of [propranolol] of EMA
Non-steroidal anti-inflammatory drugs (NSAIDS) have been reported to blunt the antihypertensive effect of beta-blocking agents.
Betablockers, prajmalium
With the co-administration of prajmalium with betablockers is to expect an additive inhibitor effect on the AV-conduction, intraventricular conduction and contraction force
Betablockers, prazosin [2] ---> SmPC of [2] of eMC
There is evidence that adding prazosin to beta-adrenergic antagonist may produce a substantial reduction in blood pressure. Therefore, the low initial dosage regimen is recommended.
Betablockers, primidone
Primidone therapy may lead to altered pharmacokinetics in concomitantly administered drugs, whose metabolism may be increased and lead to lowered plasma levels and/or a shorter half-life.
Betablockers, procaine
The co-administration may have an additive inhibiting effect on the AV conduction, intraventricular impulse spread and contractile force
Betablockers, propafenone [2] ---> SmPC of [2] of eMC
The effects of propafenone may be potentiated if it is given in combination with agents which depress myocardial activity
Betablockers, propranolol
Non-cardioselective betablocker antagonize the bronchodilator effects of bronchodilator beta agonists.
Betablockers, prostaglandin synthesis inhibitors ---> SmPC of [atenolol] of eMC
NSAIDs (especially indometacin) may reduce the antihypertensive effects of beta-blockers possibly by inhibiting renal prostaglandin synthesis and/or causing sodium and fluid retention.
Betablockers, pseudoephedrine [2] ---> SmPC of [2] of eMC
Pseudoephedrine may antagonise the effects of antihypertensive agents and severe hypertension may occur in patients receiving beta-blockers.
Betablockers, quinidine
Class I anti-arrhythmic drugs may increase atrial-conduction time and induce negative inotropic effect when administered concomitantly with beta-blockers.
Betablockers, remifentanil [2] ---> SmPC of [2] of eMC
The cardiovascular effects of remifentanil (hypotension and bradycardia), may exacerbate in patients receiving concomitant cardiac depressant drugs
Betablockers, repaglinide [2] ---> SmPC of [2] of EMA
Beta-blocking medicinal products may mask the symptoms of hypoglycaemia.
Betablockers, reproterol
Concomitant use of reproterol and betablockers may mutually weaken the effects. The administration of betablockers in patients with bronchial asthma there is the risk of severe bronchoconstriction
Betablockers, reserpine
When combined with beta-blockers, drugs that decrease arterial pressure can cause or increase hypotension, notably orthostatic.
Betablockers, reversible selective MAO-A inhibitors
Enhanced hypotensive effect of the beta-blocker but also the risk of hypertensive crisis.
Betablockers, rifabutin
Rifabutin has a similar structure as rifampicin. Concomitant use of rifabutin and betablockers may decrease betablocker effects
Betablockers, rifampicin [2] ---> SmPC of [2] of eMC
Rifampicin is a potent inducer of certain cytochrome P-450 enzymes. Coadministration of rifampicin with drugs that are also metabolised through these cytochrome P-450 enzymes may accelerate the metabolism and reduce the activity of these other drugs.
Betablockers, rilmenidine
The combination may enhance the hypotensive effect and decrease the central sympathetic tonus (reduction of heart rate and cardiac output, vasodilation)
Betablockers, ritodrine
The beta-blocker may decrease the activity of ritodrine. The co-administration should be avoided
Betablockers, rivastigmine [2] ---> SmPC of [2] of EMA
Caution should be exercised when rivastigmine is combined with beta-blockers and also other bradycardia agents
Betablockers, rocuronium [2] ---> SmPC of [2] of eMC
The acute administration of a beta-blocker increases rocuronium effects
Betablockers, salbutamol [2] ---> SmPC of [2] of eMC
Salbutamol and beta-blocking drugs such as propranolol should not usually be prescribed together.
Betablockers, salmeterol [2] ---> SmPC of [2] of eMC
Beta-adrenergic blockers may weaken or antagonise the effect of salmeterol. Both non-selective and selective beta-blockers should be avoided unless there are compelling reasons for their use.
Betablockers, salmeterol/fluticasone propionate [2] ---> SmPC of [2] of EMA
Beta adrenergic blockers may weaken or antagonise the effect of salmeterol. Both non-selective and selective betablockers should be avoided unless there are compelling reasons for their use.
Betablockers, sevoflurane [2] ---> SmPC of [2] of eMC
Sevoflurane may increase the negative inotropic, chronotropic and dromotropic effects of beta blockers (by blocking cardiovascular compensatory mechanisms).
Betablockers, sildenafil [2] ---> SmPC of [2] of EMA
Population pharmacokinetic analysis showed no effect of concomitant treatment on sildenafil pharmacokinetics when grouped as beta-adrenoreceptor antagonists
Betablockers, siponimod [2] ---> SmPC of [2] of EMA
Caution should be exercised when siponimod is initiated in patients receiving beta blockers due to the additive effects on lowering heart rate
Betablockers, sotalol
The co-administration enhances the effects of sotalol. The combination is contraindicated
Betablockers, spironolactone
The concomitant use of spironolactone and betablockers may cause hypercaliemia
Betablockers, succinylcholine ---> SmPC of [suxamethonium] of eMC
Enhancement or prolongation of the neuromuscular effects of suxamethonium by mechanisms unrelated to plasma cholinesterase activity.
Betablockers, sulfonylureas
The beta-blocker may increase the hypoglycaemic effect of sulfonylurea. Blockade of beta-adrenoreceptors may mask the symptoms of hypoglycaemia
Betablockers, sulpiride [2] ---> SmPC of [2] of eMC
The combination of sulpiride with bradycardia-inducing medications is not recommended
Betablockers, suxamethonium [2] ---> SmPC of [2] of eMC
Enhancement or prolongation of the neuromuscular effects of suxamethonium by mechanisms unrelated to plasma cholinesterase activity.
Betablockers, sympathomimetics
Concomitant use may counteract betablocker effect. Betablocker may lead to unopposed alfa-adrenergic activity of sympathomimetic with alfa- a. beta-adrenergic effect causing increased risk of hypertension, severe bradycardia a. heart block
Betablockers, tadalafil [2] ---> SmPC of [2] of EMA
Tadalafil (10 mg except for studies with angiotensin II receptor blockers and amlodipine in which a 20 mg dose was applied) had no clinically significant interaction
Betablockers, tasimelteon [2] ---> SmPC of [2] of EMA
The efficacy of tasimelteon may be reduced in patients with concomitant administration of beta adrenergic receptor antagonists.
Betablockers, temazepam
Concomitant use of betablockers and other CNS depressant drugs can mutually enhance the CNS depressant effects
Betablockers, terbutaline [2] ---> SmPC of [2] of eMC
Beta-blocking agents (including eye drops), especially the non-selective ones such as propranolol, may partially or totally inhibit the effect of beta-stimulants.
Betablockers, tetrabenazine
The co-administration of tetrabenazine with betablockers may increase the risk of orthostatic hypotension
Betablockers, tetracaine
Decreased effect of betablocker
Betablockers, thalidomide [2] ---> SmPC of [2] of EMA
Due to thalidomide 's potential to induce bradycardia, caution should be exercised with medicinal products having the same pharmacodynamic effect
Betablockers, theodrenaline
Decrease of frequency
Betablockers, theophylline [2] ---> SmPC of [2] of eMC
Co-administration of theophylline with beta-blockers may cause antagonism
Betablockers, thiazides
The hyperglycaemic effect of beta-blockers and diazoxide may be enhanced by thiazides.
Betablockers, thiazides ---> SmPC of [amlodipine/valsartan/hydrochlorothiazide] of EMA
Concomitant use of thiazide diuretics with beta blockers may increase the risk of hyperglycaemia. Thiazides potentiate the antihypertensive action of other antihypertensive drugs
Betablockers, thiopental
Thiopental will interact with beta-blockers causing a fall in blood pressure.
Betablockers, thioridazine
The combination of betablockers and phenothiazines may inhibit the metabolism and increase the plasma levels of both active substances, what may cause severe hypotension, heart rhythm disorders and adverse reactions on the CNS
Betablockers, tiapride
Bradycardia-inducing medicinal products increase the risk of ventricular arrhythmias, particularly torsades de pointes. Clinical and electrocardiographic monitoring
Betablockers, tiaprofenic acid
The NSAID can reduce the anti-hypertensive effect of beta-blocker
Betablockers, timolol ---> SmPC of [bimatoprost/timolol] of EMA
There is a potential for additive effects resulting in hypotension, and/or marked bradycardia when ophthalmic beta-blockers solution is administered concomitantly with oral beta-adrenergic blocking agents
Betablockers, tolbutamide
Betablockers have been reported to increase hypoglycaemia and to mask the typical sympathetic warning signs.
Betablockers, trandolapril/verapamil [2] ---> SmPC of [2] of eMC
The combination of verapamil with beta-blockers may provide a strong AV-conduction disturbance, which in some cases may lead to severe bradycardia: serious cardiodepression may also arise.
Betablockers, travoprost/timolol [2] ---> SmPC of [2] of EMA
The potential exists for additive effects and production of hypotension and/or marked bradycardia.
Betablockers, triamterene [2] ---> SmPC of [2] of eMC
The co-administration of triamterene and beta-blockers may enhance the hypotensive effect
Betablockers, triamterene/hydrochlorothiazide
The antihypertensive effect of triamterene/hydrochlorothiazide may be enhanced by betablockers. There is an increased risk of hyperkaliemia
Betablockers, tricyclic antidepressant ---> SmPC of [propranolol] of EMA
Drugs that induce postural hypotension may add their effects to that of beta-blockers.
Betablockers, triiodthyronine
Liothyronine accelerates metabolism of beta-blockers
Betablockers, tubocuranine
The neuromuscular blockade by peripheral muscle relaxants may be potentiate by betablockers
Betablockers, umeclidinium/vilanterol [2] ---> SmPC of [2] of EMA
Betablockers may weaken or antagonise the effect of beta2-adrenergic agonists, such as vilanterol. Concurrent use of either non-selective or selective betablockers should be avoided unless there are compelling reasons for their use.
Betablockers, vardenafil [2] ---> SmPC of [2] of EMA
Population pharmacokinetic analysis showed no effect on vardenafil pharmacokinetics of both medicinal products concomitant administered
Betablockers, vasodilators
Concomitant use of beta-blockers with vasodilatators may increase the blood pressure lowering effect.
Betablockers, verapamil [2] ---> SmPC of [2] of eMC
The combination of beta-blockers with verapamil may lead to additive cardiovascular effects (e.g. AV block, bradycardia, hypotension, heart failure).
Betablockers, vilanterol
Betablockers may weaken or antagonise the effect of beta2-adrenergic agonists, such as vilanterol. Concurrent use of either non-selective or selective betablockers should be avoided unless there are compelling reasons for their use.
Betablockers, xipamide [2] ---> SmPC of [2] of eMC
The dosage of other hypotensive drugs may require adjustment when used in conjunction with xipamide
Betablockers, zofenopril
Additive or enhanced hypotension may occur
Clonidine, non-selective betablockers ---> SmPC of [oxprenolol] of eMC
When clonidine is used in conjunction with non-selective beta-blockers, treatment with clonidine should be continued for some time after beta-blocker has been discontinued to reduce the danger of rebound hypertension.
Ephedrine, non-selective betablockers ---> SmPC of [oxprenolol] of eMC
Non-cardioselective beta-blockers enhance the pressor response to sympathomimetic drugs, resulting in hypertension and bradycardia.
Epinephrine [1], non-selective betablockers ---> SmPC of [1] of eMC
Severe hypertension and bradycardia may occur when adrenaline (epinephrine) is administered with nonselective beta-blocking medicinal products.
Isoprenaline, non-selective betablockers ---> SmPC of [oxprenolol] of eMC
Non-cardioselective beta-blockers enhance the pressor response to sympathomimetic drugs, resulting in hypertension and bradycardia.
Nateglinide [1], non-selective betablockers ---> SmPC of [1] of EMA
Non-selective beta-adrenergic-blocking agents may enhance the hypoglycaemic effect of nateglinide
Non-selective betablockers, noradrenaline ---> SmPC of [oxprenolol] of eMC
Non-cardioselective beta-blockers enhance the pressor response to sympathomimetic drugs, resulting in hypertension and bradycardia.
Non-selective betablockers, phenylephrine ---> SmPC of [oxprenolol] of eMC
Non-cardioselective beta-blockers enhance the pressor response to sympathomimetic drugs, resulting in hypertension and bradycardia.
Non-selective betablockers, repaglinide [2] ---> SmPC of [2] of EMA
Non selective beta blocking substances may enhance and/or prolong the hypoglycaemic effect of repaglinide.
Non-selective betablockers, sympathomimetics ---> SmPC of [oxprenolol] of eMC
Non-cardioselective beta-blockers enhance the pressor response to sympathomimetic drugs, resulting in hypertension and bradycardia.
Non-selective betablockers, terbutaline [2] ---> SmPC of [2] of eMC
Beta-blocking agents (including eye drops), especially the non-selective ones such as propranolol, may partially or totally inhibit the effect of beta-stimulants.
Non-selective betablockers, terlipressin [2] ---> SmPC of [2] of eMC
The hypotensive effect of non-selective beta-blockers on the portal vein is increased with terlipressin.